333 related articles for article (PubMed ID: 28332238)
1. Outcome measures for adult and pediatric hemophilia patients with inhibitors.
Hermans C; Auerswald G; Benson G; Dolan G; Duffy A; Jiménez-Yuste V; Ljung R; Morfini M; Lambert T; Osooli M; Zupančić Šalek S
Eur J Haematol; 2017 Aug; 99(2):103-111. PubMed ID: 28332238
[TBL] [Abstract][Full Text] [Related]
2. How I manage patients with inherited haemophilia A and B and factor inhibitors.
Ljung RCR
Br J Haematol; 2018 Feb; 180(4):501-510. PubMed ID: 29270992
[TBL] [Abstract][Full Text] [Related]
3. Switching haemophilia products and inhibitor risk: a United States' perspective.
Nance D; Rodgers GM
Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
[No Abstract] [Full Text] [Related]
4. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.
Ljung R; Auerswald G; Benson G; Dolan G; Duffy A; Hermans C; Jiménez-Yuste V; Lambert T; Morfini M; Zupančić-Šalek S; Santagostino E
Eur J Haematol; 2019 Feb; 102(2):111-122. PubMed ID: 30411401
[TBL] [Abstract][Full Text] [Related]
6. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
7. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
[TBL] [Abstract][Full Text] [Related]
8. Tolerance induction in hemophilia: innovation and accomplishments.
Sherman A; Biswas M; Herzog RW
Curr Opin Hematol; 2018 Sep; 25(5):365-372. PubMed ID: 29994897
[TBL] [Abstract][Full Text] [Related]
9. The management of hemophilia patients with inhibitors.
Nilsson IM
Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
[No Abstract] [Full Text] [Related]
10. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
11. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
Wu RH; Wei QQ
Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
[No Abstract] [Full Text] [Related]
12. Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.
Iioka F; Shimomura D; Nakamura F; Ohno H; Yada K; Nogami K; Shima M
Haemophilia; 2014 Nov; 20(6):e402-4. PubMed ID: 25354772
[No Abstract] [Full Text] [Related]
13. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
Astermark J; Rocino A; Von Depka M; Van Den Berg HM; Gringeri A; Mantovani LG; Morado M; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2007 Jan; 13(1):38-45. PubMed ID: 17212723
[TBL] [Abstract][Full Text] [Related]
14. The current state of adverse event reporting in hemophilia.
van Vulpen LF; Saccullo G; Iorio A; Makris M
Expert Rev Hematol; 2017 Feb; 10(2):161-168. PubMed ID: 28013565
[TBL] [Abstract][Full Text] [Related]
15. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.
DiMichele DM; Kroner BL;
Thromb Haemost; 2002 Jan; 87(1):52-7. PubMed ID: 11848456
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis in real life scenarios.
Fischer K; Konkle B; Broderick C; Kessler CM
Haemophilia; 2014 May; 20 Suppl 4():106-13. PubMed ID: 24762285
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitor development after changing FVIII/IX products in patients with haemophilia].
Kocher S; Asmelash G; Makki V; Müller S; Krekeler S; Alesci S; Miesbach W
Hamostaseologie; 2012; 32 Suppl 1():S39-42. PubMed ID: 22961330
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis in children with haemophilia - the Polish experience.
Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
[No Abstract] [Full Text] [Related]
19. Allergy and inhibitors in hemophilia - a rare complication with potential novel solutions.
Levy-Mendelovich S; Livnat T; Barg AA; Kidon M; Brutman-Barazani T; Kenet G
Blood Cells Mol Dis; 2020 Feb; 80():102370. PubMed ID: 31669933
[TBL] [Abstract][Full Text] [Related]
20. Overview of inhibitors.
Astermark J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
